The debate over the use of Embryonic stem cells and the questionable effectiveness of adult stem cells have led many scientists and clinicians to concentrate their energies on umbilical-cord-derived stem cells from healthy newborn babies. Amassing a very respectable track record in terms of safety and clinical utility, cord-blood stem cells can treat many diseases such as multiple sclerosis, amyotrophic lateral sclerosis, stroke, diabetes, heart disease and certain degenerative eye disorders.

Though largely unknown, vitamin K is critical for our health. It is needed for the normal clotting of blood and for the formation and maintenance of healthy bones. Although vitamin K2-- also called menaquinone--is naturally produced by some of our intestinal bacteria, only a limited amount of this essential vitamin is stored in our bodies. A lack of this vitamin, which can be caused by a poor diet and the regular use of certain drugs such as antibiotics, is not uncommon. Now, a new supplemental form of vitamin K, specifically vitamin K2--menaquinone-7 (MK-7)--is becoming more widely available to health consumers. It is showing great promise as a natural treatment for heart disease and bone loss. Available in soy products and as a nutritional supplement, MK-7 is clinically proven to be safe and effective. It may also be helpful for lowering cholesterol levels, preventing Alzheimer's disease, and treating some forms of cancer. And MK-7 is a powerful antioxidant without side effects.

We are standing at the threshold of a new and exciting medical era-an era of regeneration, rejuvenation, and renewal in which stems cells will set the stage for healing and in some cases, the restoration of injured, diseased, and debilitated tissues and organ. While stem cell therapy is still in its infancy, the field is rich with promise. The debate over the use of embryonic stem cells and the questionable effectiveness of adult stem cells have led many scientists and clinicians to concentrate their energies on umbilical-cord-derived stem cells from healthy newborn babies. While these cells are technically classifed as "adult stem cells," they appear to have greater restorative and regenerative potential than stem cells derived from adult tissues due to their young age. Human umbilical-cord stem cells (hUCSCs) have demonstrated great efficacy in promoting the healing of many conditions. In the last decade or so, pure cord-blood stem cells have been used by physcians to treat a mulitude of intractable diseases such as progressive multiple sclerosis, amyotrophic lateral sclerosis, certain degenerative eye disorders, stroke, diabetes, and various forms of heart disease. While certainly no cure all, umbilical-cord stem cell therapy appears to be amassing a respectable track record in terms of both safety and clinical utility. In "Umblical Cord Stem Cell Therapy: The Gift of Healing from Health Newborns", Drs. steenblock and Payne share some of the science that underlies stem cell therapy and put a human face on this field with accounts of people who have benefited from hUCSC treatments. And, in providing this information, they encourage readers to take that bold first step into this vast and wondrous medical frontier.